Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Serono" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Serono for you to read. Along with our medical data and news we also list Serono Clinical Trials, which are updated daily. BioPortfolio also has a large database of Serono Companies for you to search.
In this episode of PharmaTelevision News Review, Paul Larsmon talks with Roel Bulthuis, Head at Merck Serono Ventures. Filmed at BIO-Europe 2009, they discuss: • Merck Serono's new corporate venture fund • the motives behind the new venture fund • how investees can still develop other partnerships • a typical deal for Merck Serono under the new fund model • how early Merck Serono invests...
In this episode of PharmaTelevision News Review, Fintan Walton talks to Roel Bulthuis, Head of Merck Serono Ventures of Merck Serono SA
In March 2009 Merck Serono announced that they had set up a strategic Venture Fund to invest in biotech companies with interesting programmes that are in line with Merck Serono’s strategic thinking. At BIO 2009 Dr. Jöern-Peter Halle, VP Early Stage Licensing, joined Fintan Walton to discuss how this fund will give the company enviable access to exciting innovation in their main therapy areas.
In this episode of PharmaTelevision News Review, Fintan Walton talks to Phillippe Lopes-Fernandes, Corporate VP, Head of Global Business Development at Merck Serono
In this episode of PharmaTelevision News Review, filmed at BioEurope Spring 2013, in Barcelona, Spain, Fintan Walton talks to Philippe M Lopes-Fernandes, Senior VP, Head of Global Licensing, Business Development and Alliance Management at EMD Serono.
Merck Serono suspends trials of Stimuvax cancer vaccine after encephalitis case
Sussman to lead the company's government policy strategy and advocacy efforts
Acquires Merck Serono’s diabetes candidate imeglimin as part of the deal
Physiomics' share price surged on a €500,000 contract for its virtual tumour software with Merck KgaA.
Cladribine Tablets data to be presented includes poster presentations highlighting post-hoc analyses of the CLARITY, CLARITY Extension and ORACLE-MS trials evaluating safety and use in Read more...
Top stories on September 14th, 2009: Price-cutting: why J&J wants to pay less for Elan The year's biggest IPO: Talecris plans to raise more than US$800m The good and the bad for Merck Serono Medgenics groundbreaking biopump technology And snorting stem cells: how the nose could be the door to the brain
Merck wird 350 Jahre alt und ist somit das älteste chemisch-pharmazeutische Unternehmen der Welt. Akquisitionen wie Serono, Millipore, Sigma-Aldrich sorgen dafür, dass sich Merck in neuer Größe und...
Top stories on November 24th, 2009: Cephalon's Cinquil set-back Biogen CEO attacked over share sales and pay Merck Serono plans global R&D centre in China Norway's Clavis in US$ 380M development deal Action Shares Teva "jumps gun" with Novartis generic "Take your tablets!" -
Top stories on January 5th, 2010: Targeting cancer: RNAi minnow in billion plus pact Wrinkle power: Merz’s move into aesthetic medicine Genzyme's "fill and finish" deal with Hospira Action Shares Venturing forth: Merck Serono's 40M Euro investment fund The C factor: How a humble vitamin fights accelerated ageing
A look at today's forthcoming news stories: Pfizer and GSK in cut price vaccine deal for world's poorest; Merck Serono suspends trials of cancer vaccine after patient develops encephalitis, and Dynavax hepatitis vaccine equals GSK's rival in safety trials
Top stories on November 10th, 2009: R&D rationalisation: Pfizer closes sites and slashes jobs Enzon sells off speciality pharma business Indian generics circle Lipitor Action shares Ranbaxy's issues with FDA will take "a long time" to resolve Merck Serono Ventures seeks early stage biotechs for investment
EMD Serono Inc.'s Head of external innovation Ravi Kiron outlines to Brian Yang how the Merck KGAA Group is courting...
Jim MIllen, Physiomics Plc's chief executive, explains how the trend towards personalised medicines will aid the commercialisation of its virtual tumour software. UK development agency Innovate has given the group two grants to help with research in the area. That follows deals with two large pharmaceutical companies and a biotech this year for the cancer modelling software. Physiomics had...
Cancer drug developer Dragonfly Therapeutics has appointed Jean-Marie Cuillerot to become its chief medical officer. Cuillerot’s experience in immunotherapy includes posts at Bristol-Myers Squibb (NYSE: BMY) and Merck Serono. Last year, Waltham, MA-based Dragonfly landed a partnership with Celgene (NASDAQ: CELG) that paid the startup $33 million up front to develop up to four blood […]
Fintan Walton, CEO of PharmaVentures, talks exclusively to Bruce Carter, President and CEO of ZymoGenetics, a company that celebrated its 25th anniversary on 22 June 2006. Bruce discusses a number of aspects of ZymoGenetics' operations, including its relationship with previous owners Novo Nordisk, its alliance with Serono and its drug development model. Bruce also shares his views and advice on bi...
Xenon Pharmaceuticals (NASDAQ: XENE) announced that Ernesto Aycardi will become the company’s chief medical officer. Aycardi, a neurologist, comes to Burnaby, British Columbia-based Xenon from Teva Pharmaceutical (NYSE: TEVA), where he was a vice president. His experience also includes positions at EMD Serono, Biogen Idec, and Merck (NYSE: MRK). Xenon is developing treatments for neurological [&...
Infectious disease-focused Theratechnologies Inc. netted $55.2mm (including full exercise of the overallotment) in a bought d...
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Medical Publication Manager Oncology (Rockland or Billerica) .MA-Billerica, A career with EMD Serono is an ongoing journey of discovery: our 52,000 people are shaping how the world lives, … Continue reading → Cet article #jobs #lifescience Medical Publication Manag...
MS Ventures is the strategic, corporate venture arm of the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. They invest globally in emerging biotechnology companies that develop products and or technologies that have the potential to significantly improve patient outcomes. Along with the €100 million MS Ventures fund, their team also manages the €30 million Entrepreneur Partnershi...
SummaryEMD Serono Inc EMD, formerly Serono Inc, a subsidiary of Merck KGaA is a healthcare products provider that offers oncology products. The company offers neurology and immunology; metabolic endocrinology, fertility and oncology products. It offers neurology and immunology products to find new treatment options for drugs and combines approaches that target T and Bcell biology; cytokines and ch...